Xencor Has Been Notified Janssen Will Terminate Its Rights To Plamotamab Under License Agreement; Xencor To Regain Exclusive Worldwide Rights To CD20 x CD3 Bispecific T-Cell Engager
Portfolio Pulse from Benzinga Newsdesk
Xencor has been notified that Janssen will terminate its rights to Plamotamab under their license agreement. As a result, Xencor will regain exclusive worldwide rights to the CD20 x CD3 bispecific T-cell engager.
June 13, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Janssen, a subsidiary of Johnson & Johnson, will terminate its rights to Plamotamab under its license agreement with Xencor. This may indicate a strategic shift or reallocation of resources within Janssen.
The termination of the license agreement may reflect a strategic decision by Janssen to focus on other projects. The impact on Johnson & Johnson's overall business is likely to be minimal given its diverse portfolio.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 50
POSITIVE IMPACT
Xencor will regain exclusive worldwide rights to Plamotamab after Janssen terminates its license agreement. This could provide Xencor with new opportunities to develop and commercialize the CD20 x CD3 bispecific T-cell engager.
Regaining exclusive rights to Plamotamab allows Xencor to fully control the development and commercialization of the drug, which could lead to new partnerships or increased revenue if the drug proves successful.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100